Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Novacyt ( (FR:ALNOV) ).
Novacyt announced its monthly update regarding its liquidity agreement with Invest Securities, highlighting the purchase and sale of ordinary shares. During January 2025, 70,768 shares were bought and 75,739 shares were sold under the agreement, with shares held in treasury at the month’s end. The total number of shares in circulation is 70,626,248, which shareholders can use to calculate their interest changes. The liquidity agreement governs share transactions and was approved for a maximum purchase price of €5 per share, with a two-year initial term and annual extensions.
More about Novacyt
Novacyt is an international molecular diagnostics company that provides a wide range of integrated technologies and services, primarily focused on genomic medicine. It develops and commercializes molecular assays and instruments, offering solutions across sectors such as human health, animal health, and the environment. The company is structured into three segments: clinical in vitro diagnostics, next-generation instrumentation, and research services for the life sciences industry. Headquartered in Le Vésinet, France, with offices in the UK, Singapore, the US, and Canada, Novacyt is listed on the London Stock Exchange’s AIM market and Paris Stock Exchange’s Euronext Growth.
YTD Price Performance: 6.28%
Average Trading Volume: 287
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $45.98M
For detailed information about ALNOV stock, go to TipRanks’ Stock Analysis page.
